Board Changes

TORONTO, ONTARIO – May 28, 2025 – OB Pharmaceuticals, Inc. announces the retirement of two founding Board members, Andrew Clarke and Barry Pickford at the beginning of this year. The company is extremely grateful for the dedicated leadership and expertise that Andrew and Barry have contributed over the years since OB Pharma’s inception. In their places, the company welcomes Dr. Caroline Schild-Poulter and Mr. Rod Prat to the Board. Dr. Schild-Poulter received her PhD in molecular biology at the University of Lausanne, Switzerland and completed a post-doctoral fellowship at the National Institutes of Health in the U.S. She is currently a full professor at the Robarts Research Institute, Western University, London, ON. Mr. Prat has maintained an extensive career in private and public sector capital markets and financial modelling/risk management including 20 years with Goldman Sachs, HSBC and Deutsche Bank in Toronto, Chicago, NYC and London following with British Columbia Investment Management in Victoria, BC.